Hetero launches combination drug for HIV under brand name Taffic
The Hyderabad-based company has introduced the 3-in-1 drug under the brand name 'Taffic' in India.
The company's product is a generic version of Gilead's Biktarvy and has been approved by the Drug Controller General of India (DCGI).The product will be marketed and distributed by Hetero Healthcare Ltd in the country, the drug firm said in a statement.
To further this mission, Hetero will be making the latest combination drug available in 116 low and middle-income countries upon approvals from the regulatory authorities there, the drug firm said.Taffic, a once-a-day single pill, is a combination of three medicines -- Bictegravir (50mg), Emtricitabine (200mg) and Tenofovir Alafenamide (25mg).
It is indicated for treatment of HIV-1 infection in adults who have no antiretroviral treatment history.The drug can also be used to replace the current antiretroviral regimen in those who have viral copies less than 50 per ml in the blood at least for three months with no prior treatment failure and resistance to any components. Hetero would manufacture the product at its manufacturing facility in Hyderabad, which is approved by international regulatory bodies.
(This story has not been edited by Business Insider and is auto-generated from a syndicated feed we subscribe to.)
- Rashtriya Ekta Diwas: Famous quotes by Sardar Vallabhbhai Patel
- Modi to launch India's first seaplane service tomorrow
- Karwa Chauth 2020: Date, puja time, and everything you need to know
- UNESCO allots India’s Panna Tiger Reserve ‘Biosphere Reserve’ status after it brought its tiger population back from zero to 54 in ten years
- BCG vaccine can help elderly fight against Covid-19: ICMR study